Bioavailability of the Tablet Dosage Form of a Benzimidazole Derivative Possessing Antiplatelet Activity

The bioavailability of the tablet dosage form of pharmaceutical substance RU-891, i.e., 9-(3,4-dihydroxyphenacyl)-2,3-dihydroimidazo[1,2- a ]benzimidazole hydrobromide, was investigated. The main pharmacokinetic parameters were determined. The relative bioavailability index was estimated at 93.98%. No evidence of drug accumulation from an RU-891 270-mg tablet dosage form was detected in rabbits upon threefold administration at a dose of 23 mg/kg.